Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14699465 | 0.79 | CETP (0.54) | CETP | |
| SCHEMBL664932 | 0.78 | PIK3CD (0.36) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14697586 | 0.74 | CETP (0.33) | CETP | |
| SCHEMBL662196 | 0.73 | CETP (0.55) | CETP | |
| SCHEMBL12424402 | 0.73 | CETP (0.55) | CETP | |
| SCHEMBL662673 | 0.71 | ALDH1A1 (0.36) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16360358 | 0.68 | CETP (0.41) | CETP | |
| SCHEMBL663984 | 0.68 | CETP (0.41) | CETP | |
| SCHEMBL21663157 | 0.59 | CDK4 (0.32) | — | |
| SCHEMBL662554 | 0.58 | CETP (0.39) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760868-B1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-2760868-B1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2018-04-25 | — | — | EP | disclosed |
| US-9150583-B2 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150583-B2 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150583-B2 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2760868-A1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| WO-2013024130-A1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024130-A1 | FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210850-A1 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | CETP, MTTP, NPC1L1 | CETP 1/4885PIK3CD 4368/4885PIK3CA 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.